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Abstract
Hutchinson‐Gilford Progeria Syndrome (HGPS) is a devastating premature aging dis-
ease. Mouse models have been instrumental for understanding HGPS mechanisms
and for testing therapies, which to date have had only marginal benefits in mice and
patients. Barriers to developing effective therapies include the unknown etiology of
progeria mice early death, seemingly unrelated to the reported atherosclerosis con-
tributing to HGPS patient mortality, and mice not recapitulating the severity of
human disease. Here, we show that progeria mice die from starvation and cachexia.
Switching progeria mice approaching death from regular diet to high‐fat diet (HFD)
rescues early lethality and ameliorates morbidity. Critically, feeding the mice only
HFD delays aging and nearly doubles lifespan, which is the greatest lifespan exten-
sion recorded in progeria mice. The extended lifespan allows for progeria mice to
develop degenerative aging pathologies of a severity that emulates the human dis-
ease. We propose that starvation and cachexia greatly influence progeria pheno-
types and that nutritional/nutraceutical strategies might help modulate disease
progression. Importantly, progeria mice on HFD provide a more clinically relevant
animal model to study mechanisms of HGPS pathology and to test therapies.
1 | INTRODUCTION
Hutchinson‐Gilford Progeria Syndrome (HGPS) is caused by LMNA
gene mutation and expression of a mutant lamin A protein called pro-
gerin, which disrupts nuclear architecture and genome stability and*These authors contributed equally to this work.
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function, promoting cellular senescence (Collins, 2016; Gonzalo &
Kreienkamp, 2015; Prokocimer, Barkan, & Gruenbaum, 2013). At the
organismal level, progerin unleashes a trove of devastating aging
pathologies including alopecia, bone and joint abnormalities, lipodys-
trophy, cardiovascular disease (CVD), and atherosclerosis (Gonzalo,
Kreienkamp, & Askjaer, 2016; Ullrich & Gordon, 2015). The progerin‐
expressing LmnaG609G/G609G mouse (herein G609G) carries the equiv-
alent human mutation in homozygosis and has been widely used for
studying the mechanistic bases underlying progeria, as well as the
outcomes of various therapeutic avenues (Osorio et al., 2011). Cellu-
lar phenotypes include nuclear morphological abnormalities, increased
genomic instability, deregulated gene expression, and premature
senescence (Gonzalo et al., 2016; Ullrich & Gordon, 2015). G609G
mice develop some progeroid features such as growth impairment,
lipodystrophy, bone abnormalities, and cardiovascular alterations
(Osorio et al., 2011; Villa‐Bellosta et al., 2013). However, these mice
die at a very young age (~100 days) of unknown etiology and do not
mimic the severity of disease of HGPS patients.
Here, we demonstrate that G609G mice succumb to starvation
and cachexia, with mice losing lean mass and white adipose tissue at
an early age and exhibiting alterations in energy utilization and
expenditure. Switching mice nearing death from regular chow (RC)
to high‐fat diet (HFD), with higher caloric content, rescues early
lethality and significantly improves organismal decline. Importantly,
G609G mice placed on HFD in the first month of life nearly double
their lifespan and, during their extended survival, they develop
HGPS‐like pathologies including severe alopecia, skeletal dysplasia,
and aortic wall stiffening. Collectively, our data demonstrate the
importance of caloric intake to G609G mouse phenotype, and sug-
gest that alterations in metabolism, both in humans and mice, play a
role in progerin‐induced physical decline. Thus, progeria mice on
HFD provide a unique model to identify mechanisms underlying pro-
gerin‐induced tissue toxicity and for testing therapies of relevance
for human disease.
2 | RESULTS
2.1 | Progeria mice exhibit metabolic alterations
To determine whether progeria mice exhibit metabolic alterations,
we utilized a comprehensive lab animal monitoring system (CLAMS)
coupled to open circuit calorimetry to assess energy expenditure and
whole‐body fuel selection, and NMR to assess body composition.
We placed regular chow (RC)‐fed WT and G609G mice in metabolic
cages at 7 weeks of age, before the most severe effects of progerin
were apparent. The respiratory exchange ratio (RER, the ratio of
CO2 produced from metabolism and O2 intake) reflects the source
of energy being oxidized for fuel. During the active (dark) cycle both
WT and G609G mice preferentially utilize carbohydrates (RER ~ 1),
reflecting the high‐carbohydrate content of the rodent chow diet
(58% kJ/carbohydrates). During the resting (light) cycle, G609G mice
displayed a more robust decline in RER compared to WT mice, sug-
gesting a stronger preference for utilizing fat or protein as fuel (Fig-
ure 1a). The same G609G mice also expended less energy (produced
less heat) compared to WT mice (Figure 1b). Energy expenditure (EE)
is significantly lower in G609G mice when adjusted for body mass/
composition and physical activity, both in the dark and light cycles,
and over a 24‐hr period. These differences in RER and EE were
accompanied by changes in activity and sleep. G609G mice slept
more during the dark cycle and were less active than WT mice at all
times (Figure 1c). Importantly, 7‐week old G609G mice behaved dif-
ferently from WT during voluntary physical exertion (Figure 1d).
During the first week after placing mice in wheel running cages, WT
mice ran more as they became accustomed to the wheel. In contrast,
G609G mice ran less with each consecutive day, indicating potential
exhaustion. Our data show that RC‐fed G609G mice have alterations
in metabolic rate evidenced by changes in energy expenditure and
declining activity, which is consistent with a physiological alteration
to conserve energy.
F IGURE 1 Characterization of metabolism of G609G mice. Comprehensive lab animal monitoring system (CLAMS) was utilized to compare
whole body fuel selection, indicated by the respiratory exchange ratio (RER), and energy expenditure between WT and G609G mice at
7 weeks of age (all males). (a) RER was measured every hour for a period of 60 hr in 6 WT mice and 5 G609G mice. Left graph shows raw
data in 1‐hr bins, with the dark phase indicated by a black bar. Right graph shows averaged values during light and dark phases, and over 24 hr
(right panel). Total number of values averaged: 144 for WT and 120 for G609G mice. RER in WT and G609G mice is significantly different
during the lights‐on phase (***p < 0.005). (b) Energy expenditure (EE) in the same mice as in (a). EE is significantly lower in G609G mice
compared to WT when adjusted for body mass/composition and physical activity. Left graph shows raw data adjusted for lean mass as 1‐hr
bins, with the dark phase indicated by a black bar. Right graph shows the results from an EE analysis using ANCOVA where body weight, body
composition –FM (fat mass), FFM (fat‐free mass)‐ and physical activity were included as covariates. An analysis using linear regression indicates
body weight, FFM and activity are significant predictors in the model for EE over 24 hr. Total number of values averaged: 144 for WT and
120 for G609G mice. (c) Monitoring of activity and sleep in the same mice as in (a) during the light and dark cycles. (d) Locomotor activity was
recorded daily using 7‐week old mice housed in cages with free access to running wheels. N = 11 mice per group. (e) Graph shows mass
recorded daily for male mice. G609G mice have reduced mass, with a slower rate of gain and lower plateau than WT mice. N = 12 mice per
group. (f,g) Body mass composition of male WT and G609G mice from 6 to 16 weeks of age. N = 10 for each group. (h) Necropsy pictures of
11 weeks‐old male mice. Notice the reduction in abdominal/subcutaneous fat in G609G mice. (i) Food intake (% body weight ingested per day
per mouse) calculated daily in single‐housed WT (N = 10) and G609G (N = 9) mice fed RC diet since weaning. Measurements performed from
weeks 8 to 11 of age. (j) Eating behavior as number of meals in the dark and light cycles of WT (n = 14) and G609G (n = 7) male mice.
Recording was performed during 5 days using BiodaQ 2.3 system. (k) Monitoring of total number of meals and bouts (left graphs), and time
(seconds) spend per meal/bout over the 5‐days period. In all figures, * denotes p value of statistical significance (*p < 0.05; **p < 0.01;
***p < 0.005; ****p < 0.0001), and error bars represent standard error of the mean (SEM)
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At birth, G609G mice are indistinguishable from their WT litter-
mates, but by 4 weeks of age they are significantly smaller (Fig-
ure 1e). This is similar to HGPS patients, who are normal at birth but
gradually develop growth defects, often never reaching a total body
mass of 30 kg (Kieran, Gordon, & Kleinman, 2007). Finding the
source of body mass loss with age in G609G mice is important for
understanding its underlying cause. Hence, we monitored body com-
position in WT and G609G mice weekly using NMR. Interestingly,
changes in G609G mass were predominantly driven by loss of lean
mass (Figure 1f). By six weeks of age, G609G mice reached their
maximum lean and total body mass, and both values progressively
declined thereafter. Fat and fluid masses also peaked at six to seven
weeks before declining but were relatively smaller contributors to
the total body mass loss (Figure 1g). At necropsy, G609G mice had
less abdominal and subcutaneous fat than their WT littermates (Fig-
ure 1h). This is consistent with previous reports of lipoatrophy in
G609G mice due to persistent DNA damage and senescence of adi-
pocytes (Osorio et al., 2011; Revêchon et al., 2017). In summary, our
results suggest an energy deficit in G609G mice and features of star-
vation and cachexia, with mice progressively losing muscle and adi-
pose tissue with age.
To determine if there were differences in food consumption that
could explain the decline in body mass over time in G609G mice, we
monitored daily food intake (FI = % body weight consumed per day
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per mouse) of single‐housed mice for 4 weeks. We observed a FI
reduction in G609G mice compared to WT by 9 weeks of age (Fig-
ure 1i), as well as changes in eating behavior. Normally, mice eat
more during the dark cycle, when they are more active, than during
the light cycle. In contrast, G609G mice eat at a comparable rate
during the dark and light cycles (Figure 1j). Moreover, while the
number of meals/bouts are less in G609G mice compared to WT,
the time spent in each meal/bout is larger in G609G mice (Figure 1k).
In fact, they seemed to be eating constantly while awake, even dur-
ing the light cycle (Supporting information Video S1). These alter-
ations in FI and eating behavior might contribute to the starvation
phenotype of G609G mice fed a RC diet.
2.2 | HFD ameliorates progerin‐driven mortality
G609G mice exhibit features of both starvation, which stems from
lack of adequate energy intake, and cachexia, driven by an intrinsic
process independent of energy intake (Argiles, Busquets, Stemmler,
& Lopez‐Soriano, 2014; Thomas, 2007). Since starvation can be ame-
liorated by increased energy consumption, while cachexia generally
cannot, we tested whether a high‐fat diet (HFD; 60% calorie from
fat) could improve the G609G mouse phenotype. Hence, as G609G
mice approached terminal stage (11 weeks of age), we switched their
diet from RC to HFD. Remarkably, the G609G mice immediately
responded in a positive manner. In 4 days, the G609G mice gained
two grams, a 15% increase in total body mass, while the WT mice
showed no change in body mass (Figure 2a). G609G mice fed HFD
maintained body mass for three weeks but began to fall by four
weeks. NMR analysis indicated that increased lean mass was primar-
ily responsible for increased body mass in G609G animals (Figure 2b).
Fat mass was maintained in G609G mice while on HFD. This is in
contrast with the WT mice, which gained fat mass at a linear rate
over the 4‐week HFD regimen. Importantly, while in this particular
experiment, all G609G mice on RC were dead before reaching
100 days of age, all mice on HFD were alive and seemed healthy
30 days after the HFD switch.
We then determined if there were differences in daily FI that
could explain the improvement after the switch to HFD. Figure 2c
represents weekly averages of daily FI. WT mice switched to HFD
exhibit a marked reduction in FI, given the higher caloric content of
the HFD. In contrast, G609G mice continue to ingest similar
amounts of food after the switch, and with the greater caloric den-
sity of the HFD they are consuming increased calories (Figure 2c).
Thus, ingesting HFD, with higher caloric content, is able to improve
morbidity and rescue early lethality, suggesting that starvation is
contributing to the decline and early death of G609G mice. In addi-
tion to changes in FI, we tested for deficiencies in nutrient absorp-
tion in G609G mice with respect to WT mice, as intestinal
malabsorption could contribute to starvation and cachexia pheno-
types. WT and G609G mice were administered a radioactive lipid
(14C‐oleic acid) by oral gavage, followed by detection of radioactivity
in plasma. Interestingly, G609G mice absorb significantly more fatty
acids than WT mice (Figure 2d). We also monitored cholesterol
excretion in feces. WT and G609G mice were switched to a high‐c-
holesterol diet, and the amount of cholesterol excreted in the feces
in 1 day quantitated 20 days after the switch. G609G mice displayed
less excretion of cholesterol compared to WT mice (Figure 2e), sug-
gesting a potential increase in absorption. We propose that
increased nutrient absorption by G609G mice might be a mechanism
to compensate for reduced FI in these mice.
Importantly, HFD feeding resulted in additional phenotypic
improvements in G609G mice: they slept less and were less lethargic
after switching to HFD than before starting the diet (Figure 2f and
Supporting information Video S2). At necropsy, HFD‐fed G609G ani-
mals exhibited abdominal fat which was not evident in RC‐fed mice,
although fat deposits were still reduced compared to either RC‐ or
HFD‐fed WT mice (Figure 1c and 2g). Adipose tissue histology
revealed decreased adipocyte size in RC‐fed G609G mice with
respect to WT mice (Figure 2h). Mice switched to HFD show an
increase in adipocyte size, however the increase is more robust in
WT mice (Figure 2i). These results are consistent with severe lipoat-
rophy in progeria mice, which is ameliorated by HFD. Overall, our
data suggest that G609G mouse mortality is driven by starvation
and cachexia. While switching G609G mice from RC to HFD pro-
vides the source of energy needed to extend their lifespan, the ben-
eficial effect appears to be only temporary.
2.3 | HFD doubles lifespan of progeria mice
Given the benefits of switching RC‐fed G609G mice nearing death to
HFD, we tested whether early HFD feeding had a more robust and
sustained effect, and whether other diets might affect morbidity and
mortality. To this end, we allocated mice to one of the three groups
after weaning: RC, HFD, or a high‐protein diet (HPD). To ensure that
phenotypic differences that developed between diets were due to
nutritional differences and not edibility and palatability, all diets were
provided both as pellets and grounded, so mice across all diets had
access to soft food. Tracking of body mass (Figure 3a) revealed that
mice in the HPD and RC groups behaved similarly, reaching an aver-
age maximum mass of 18.2 and 17.8 g, respectively, at 6 weeks of
age and declining thereafter. In contrast, HFD‐fed G609G animals
reached a maximum body mass of 20.3 g, 14% higher than that of
RC‐fed mice, at 9 weeks. Thus, HFD raised the maximum body weight
and delayed the body mass inflection point, indicating that HFD slows
the decline of G609G mice. Lean, fluid, and fat masses followed simi-
lar trends (Figure 3b). RC‐fed and HFD‐fed mice reached similar maxi-
mum lean masses, but with a difference of 4 weeks (at 6 and
10 weeks, respectively), demonstrating that HFD delays lean mass
loss in G609G mice. Maximum fluid mass was greater in HFD‐fed
mice and was reached at week nine compared to week six in RC and
HPD mice. Fat mass mirrored this pattern as well.
The most striking effect of the different diets was on lifespan
(Figure 3c). G609G mice maintained on RC and HPD lived 111 and
113 days on average respectively. Their maximum lifespans were
122 and 120 days respectively. However, as the RC and HPD mice
began to die, HFD mice remained in robust health. In fact, G609G
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mice continued to thrive and lived for 193 days on average (~75%
increase in lifespan). Notably, this is the largest lifespan extension
reported to date in G609G mice. The maximum lifespan was
229 days, which doubled the average lifespan of RC‐fed mice. Given
this robust effect of HFD, we tested whether a high‐cholesterol diet
(HCD) might impact lifespan, since this diet has an intermediate calo-
rie and fat content compared to HFD. Interestingly, mice on HCD
lived an average of 169 days, which was significantly longer than the
HPD and RC, but still less than the HFD. Therefore, diets with
increased energy content had the greatest beneficial effect on
G609G mice. Fat content was also important, as lifespan was identi-
cal for G609G mice in the fat‐equivalent HPD and RC, despite the
HPD providing 30% more energy content overall. We conclude that
increasing dietary energy content, and especially fat content, delays
the onset of starvation and cachexia driving RC‐fed G609G mouse
death, thus significantly extending their lifespan.
F IGURE 2 Robust response of progeria mice to high‐fat diet. (a) Male G609G mice (N = 5) and WT (N = 6) controls were switched to a
HFD (60% calories from fat) at 11 weeks of age, and cumulative mass change from starting mass was recorded daily. Picture shows mice
4 days after the switch to HFD, a point at which G609G mice experienced a 15% increase of their body weight. (b) The same mice as in (a),
switched to HFD, were placed in NMR weekly to determine lean mass and fat mass changes from the initial mass. (c) Food intake (% body
weight ingested per day per mouse) in G609G and WT mice fed RC (weeks 9 and 10) and switched to HFD for 4 weeks (weeks 11–14). Mice
were single‐housed, and food consumption monitored daily. Graph shows FI weekly average ± SEM (N = 5 male mice per group). (d) G609G
mice (N = 10) and WT controls (N = 9) seven weeks of age were administered 14C‐oleic acid via gavage and 3 hr later radioactivity in plasma
measured. Aborption calculated as pmol of 14C‐oleic acid per gram (body weight) per hour. Half mice were males and half females. (e) Single‐
housed male G609G mice (N = 5) and WT controls (N = 5) were switched to a high cholesterol diet (HCD) at 7 weeks of age. Daily feces were
collected twenty days after the switch. Note how the amount of cholesterol excreted in the feces is significantly reduced in G609G mice with
respect to WT. (f) Change in percentage sleep immediately after mice were switched to HFD compared to sleep pattern on RC. (g) Necropsy
images of WT and G609G mice switched from RC to HFD and maintained on HFD for four weeks. Notice adipose tissue is evident in
abdominal cavity of G609G mice, which was not previously present for mice on RC (Figure 1d). (h) Images from histology of H&E stained
adipose tissue from WT and G609G mice fed RC. (i) Graph shows quantification of adipocytes size in G609G (N = 9) and WT (N = 10) mice
fed RC up to 11 weeks of age, and in mice switched from RC to HFD at 11 weeks of age and maintained in HFD for 4 weeks (N = 5 in each
group of both G609G and WT mice)
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F IGURE 3 Delayed aging phenotypes and extended lifespan of G609G mice fed HFD. (a) Mass was recorded daily for male G609G mice
fed RC (N = 12), HFD (N = 11), or high‐protein diet (HPD; N = 7) since weaning. Note the sustained increase in body mass of G609G mice on
HFD. (b) Lean, fluid, and fat mass composition as measured by NMR in male G609G mice fed RC, HFD or HPD from 6 to 25 weeks of age. (c)
Kaplan–Meier survival curves of male WT and G609G mice fed RC (N = 12), HFD (N = 11), HPD (N = 7), and HCD (N = 7; a diet consisting of
40% fat content + cholesterol). (d) Blood glucose monitored for groups of mice fed RC or HFD since weaning and fasted for 6 hours: WT RC
(N = 13), G609G RC (N = 12), WT HFD (N = 7), and G609G HFD (N = 10). Analysis at 11 weeks of age. (e) Insulin levels measured for WT and
G609G mice fed RC (~11 weeks of age) or HFD (~22 weeks of age): WT RC (N = 9), G609G RC (N = 7), WT HFD (N = 8), G609G HFD
(N = 4). Mice were fasted for 3 hours prior to collecting blood for analyses. WT mice develop hyperglycemia and hyperinsulinemia on HFD,
while G609G mice do not. (f) Concentrations of phosphatidylcholines, lysophosphatidylcholines, cholesteryl esters, and free fatty acids as
determined by mass spectrometry. Female G609G and WT mice were used for this study. Mice were either fed RC since weaning or switched
from RC to HFD at 11 weeks of age for four weeks (as in Figure 2a). Samples were collected at 11 weeks of age in mice on RC and at
14 weeks of age in mice switched to HFD. N = 5 in each group. (g) qRT‐PCR analysis on muscle samples (quadriceps) from WT (N = 6) or
G609G (N = 4) mice fed RC (11 weeks of age) or HFD (22 weeks of age). (h) Immunoblotting on proteins isolated from WT or G609G mouse
quadriceps at necropsy. Notice expression of progerin and increased expression of CTSL and LC3‐II in G609G mice (left panel), which are
ameliorated on HFD (right panels). Graph shows densitometry of immunoblots (average ± SEM) performed in WT (n = 6) and G609G (N = 6)
mice fed RC (11 weeks old) and G609G fed HFD (N = 4 and 22 weeks old) mice. Note the increase in LC3‐II/LC3‐I ratio and CTSL levels in
G609G mice fed RC, and the decrease in G609G mice fed HFD
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2.4 | HFD induces metabolic changes in G609G
mice
Normally, increased calorie consumption leads to a slew of detrimen-
tal side effects, including hyperglycemia and hyperinsulinemia. We
tested whether HFD consumption in G609G mice elicits detrimental
metabolic consequences normally associated with these diets. While
WT mice became hyperglycemic on HFD, G609G mice at 11 weeks
of age treated for 2 months with HFD maintained relatively normal
levels of blood glucose (Figure 3d). Moreover, G609G mice on RC
exhibit lower insulin levels than WT mice. Importantly, the robust
increase in insulin levels in WT mice fed HFD is not observed in
G609G mice (Figure 3e). G609G mice on RC also displayed impaired
glucose tolerance that was normalized by the HFD and the G609G
mice on HFD did not display signs of insulin resistance typically
observed in WT mice on this diet (Supporting information Figure S1).
A pyruvate tolerance test revealed a lower capacity of gluconeogen-
esis in G609G mice relative to WT mice that was not significantly
altered by the diet. These data indicate a distinct metabolic response
of G609G mice to HFD compared to WT mice.
To further investigate the impact of HFD on G609G mice, we
performed complete lipidomics using mass spectrometry on plasma
isolated from WT and G609G mice on RC and HFD (Figure 3f and
Supporting information Figure S2). Although the differences between
the WT and G609G mouse lipids levels were few, there were several
key differences observed. Phosphatidylcholine (PC), an abundant
component of lipid bilayers and lipoproteins, was elevated in both
WT and G609G mice upon HFD feeding, but the increase was sig-
nificantly lower in G609G mice. Lysophosphatidylcholine (LPC), a
metabolite product of PC, was selectively elevated in only the HFD‐
fed G609G mice suggesting an increase in PC degradation. Choles-
teryl esters increased in a similar fashion in both WT and G609G
mice when fed HFD. Interestingly, free fatty acid (FFA) species were
increased in G609G mice relative to WT mice, both on RC and HFD.
FFAs are known to increase with starvation (Yaffee, Gold, & Sam-
pugna, 1980). The increase in FFAs in G609G mice could also reflect
lipolysis of adipose tissue.
Muscle breakdown and dysfunction is a key characteristic of
cachexia (Thomas, 2007). Since we observed cachectic tendencies in
G609G mice, we monitored pathways with key roles in muscle
homeostasis. We found that expression of genes involved in muscle
catabolism and structure were altered in G609G mice relative to WT
mice and these alterations were ameliorated by HFD (Figure 3g).
Trim63, important for muscle protein breakdown and inhibition of
protein synthesis, is upregulated in G609G mice on RC, and HFD
restores normal levels of Trim63 expression. Interestingly, this gene
is frequently upregulated in cachexia (Cai et al., 2004; Yuan et al.,
2015). G609G mice also exhibit downregulation of Pax7, a key gene
for satellite cell survival (Lepper, Partridge, & Fan, 2011; Sambasivan
et al., 2011). Satellite cells are necessary for skeletal muscle regener-
ation and repair, and Pax7 loss can cause major disruptions in adult
myogenesis (Maltzahn, Jones, Parks, & Rudnicki, 2013). Reduced
Pax7 expression in G609G mice on RC suggests a likely deficiency in
muscle repair capacity. Importantly, mice on HFD show a marked
increase in Pax7 expression, reaching levels similar to WT mice.
Other changes in G609G muscle gene expression were not affected
by HFD. Myosin heavy chain (Mhc), the motor protein of muscle
thick filaments, is essential for proper muscle function. In G609G
mice, this gene is downregulated, and its expression is not increased
on HFD. Likewise, myostatin (Mstn), a negative regulator of muscle
growth and development that is associated with cachexia (Zhou
et al., 2010), is increased in G609G mice, and HFD does not reduce
its levels. Therefore, while HFD is able to improve some gene
expression alterations in muscle, others remain unchanged.
We also found protein alterations consistent with muscle disease
in G609G mice (Figure 3h). Cathepsin L (Ctsl) is a lysosomal cysteine
protease involved in protein degradation, known to be upregulated
during muscle wasting (Deval et al., 2001). Interestingly, cathepsin L
protein levels are increased in G609G mice, and reduced by HFD.
Similarly, LC3, an important marker of autophagy, is increased in
G609G mice on RC. This could reflect activation of autophagy in
order to generate energy. G609G mice on the HFD exhibit reduced
LC3 expression, suggesting that these mice are obtaining sufficient
energy from the diet. These analyses indicate that G609G mice phe-
notype is characterized by features of both cachexia and starvation.
2.5 | HFD‐fed G609G mice develop a more severe
progeroid phenotype
While RC‐fed G609G mice recapitulate many aspects of the human
disease, including skin, cardiovascular, and bone alterations, the
severity of these phenotypes is not as pronounced as in human
patients. Interestingly, as HFD‐fed progeria mice aged, we noticed
that these mice progressively developed pathologies that mimicked
the severity of human disease, such as thinner skin and prominent
alopecia, eye defects, and more pronounced bone dysplasia (Fig-
ure 4a). Thus, HFD did not prevent the development of progeroid
phenotypes; rather, the extended lifespan on HFD unmasked some
critical pathological characteristics of human condition.
To characterize these pathological changes more completely and
understand the prolonged effect of progerin in vivo, we examined
the bone of progeria mice maintained on HFD vs RC by conducting
µCT on the whole animal (Supporting information Figure S3) and in
tibias (Figure 4b). Interestingly, most tibia bone parameters contin-
ued to degenerate with increasing age of G609G mice on HFD.
HFD‐fed G609G mice at 200 days of age had decreased cortical
thickness (Ct. Th), bone area to total area (BA/TA), and bone mineral
density (BMD) compared to both WT and RC‐fed G609G mice at
100 days of age, indicating progressive thinning of bone.
Another organ with noticeable degeneration at necropsy was the
intestine (Figure 4c), which appeared severely inflated and filled with
air in HFD‐fed G609G mice of ~200 days of age. These intestines
had thinner muscularis (by histology) and, at certain areas, were
almost transparent. In some, it also appeared that the mice had a
severely swollen appendix. In every animal examined, there were
obvious intestinal alterations and defects.
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F IGURE 4 HFD‐fed G609G mice embody characteristics of human phenotype. (a) Pictures were taken of G609G mice on RC near death
(100 days), and on HFD at 150 and 200 days of age. Note the progressive development of progeroid features, especially allopecia. (b) X‐ray
microCT was conducted on tibiae of WT mice, G609G mice fed RC (100 days of age), and G609G mice fed HFD (200 days of age). Cortical
analyses were performed to quantify total area (TA), total bone area (BA), cortical thickness (Ct.Th, TRI method), bone mineral density (BMD),
and tissue mineral density (TMD). Pictures are representative of tibiae samples analyzed. (c) Pictures of intestines taken at necropsy of G609G
mice on HFD ~200 days old, and histological analysis performed by H&E staining. Note the alterations in intestine morphology, and the loss of
muscularis by histology. (d) Histology of skin with H&E staining shows examples of exacerbation of alterations in hair shafts of HFD‐fed
G609G mice (~200 days of age) compared to RC‐fed mice (~100 days of age), consistent with robust alopecia. Pictures were taken at two
different magnifications (5× and 10×). (e) Picture of heart and aorta taken from a HFD‐fed G609G mouse (~200 days of age) at necropsy. (f)
Histology of aortas with H&E staining shows examples of acellular and mineralized aortas in G609G mice on HFD (~200 days of age),
compared to RC‐fed WT and G609G mice (~100 days of age). Pictures taken at 40× magnification. (g) Picture shows an example of a pregnant
HFD‐fed female G609G mouse (third pregnancy). None of the RC‐fed G609G females became pregnant in our study
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G609G mice on HFD also developed pronounced skin alter-
ations, with progressive and severe alopecia (Figure 4a). Histologi-
cal analysis of skin samples revealed significantly diminished
subcutaneous fat and thinner skin, which was obvious in RC‐fed
mice, but accentuated in HFD‐fed mice as they aged (Figure 4d).
HFD‐fed G609G mice also showed fewer hair follicles and hair
shafts in the follicles, and many follicles appeared to have disor-
dered differentiation. In addition, there were cystic growths in the
dermis, suggesting atrophy of hair follicles in HFD‐fed G609G
mice.
Previous studies in G609G mice fed a normal diet showed car-
diovascular alterations, including calcification of the aorta and
reduced number of VSMCs in the aortic branch (Osorio et al., 2011;
Villa‐Bellosta et al., 2013). We find that HFD‐fed G609G mice devel-
oped aortic defects with a severity not observed previously in any
mouse model of progeria. At necropsy, the aortas appear signifi-
cantly stiffer in HFD‐fed G609G mice (~200 days of age) than in
RC‐fed mice (~100 days of age). Some of the HFD‐fed mice showed
gross morphological abnormalities, including in some situations
where the aorta became fused to the heart (Figure 4e). However,
the most dramatic phenotype was observed in histological sections
(Figure 4f and Supporting information Figure S4). The ascending
aorta, descending aorta, and aortic arch showed mineralization of
the media, thickening of the adventitia, and broad acellularity in both
the media and the adventitia, with a profound loss of VSMCs. In
addition, elastic fibers appeared stretched, a phenotype consistent
with alterations in aortic mechanical properties. This severe aortic
phenotype could play a major role in the decline and death of
G609G mice on HFD. Of note, despite the aortic stiffening, we did
not find signs of atherosclerosis in the aorta, but this was not unex-
pected given that the mice were not in a hypercholesterolemic back-
ground.
Another interesting observation was that, unlike the G609G mice
maintained on RC, HFD‐fed G609G female mice were able to
become pregnant and deliver viable litters (Figure 4g). G609G mice
have been previously characterized as infertile and our observation
is consistent with an improvement in their health due to mainte-
nance on high energy diet. While these mothers have been unable
to care for their litters to this point, possibly as a result of lack of
milk production, the ability of these females to carry a full litter to
term is impressive. In summary, HFD improves the G609G mouse
phenotype in many ways. Most significant is the fact that G609G
HFD‐fed mice overcome the starvation phenotype driving early
lethality to unveil important human‐like phenotypes.
3 | DISCUSSION
Our study demonstrates the importance of caloric intake to the
development of various phenotypes in G609G mice. The finding that
HFD results in the largest extension of life recorded to date in an
HGPS mouse model suggests that a nutritional/nutraceutical
approach could provide a powerful tool for modulating disease
course in both mice and humans. Interestingly, the Progeria Research
Foundation recommends feeding high calorie foods to HGPS
patients:
Children with Progeria actually eat enough calories to
grow, but the basic disease process in Progeria does
not allow them to grow normally. Some parents also
report that the children tend to take in smaller, more
frequent meals. Therefore, the goal is to give them
nutritious and high calorie foods and supplements.
Our finding that dietary intervention results in both lifespan
extension in G609G mice and in the development of aging pheno-
types with a robustness that emulates the human syndrome is in line
with studies in other mouse models of progeria. For instance, in
mouse models of Cockayne syndrome, feeding pregnant dams HFD
rescues death around weaning, thus revealing symptoms of neurode-
generation later in life that are much more emblematic of the human
disease (Brace et al., 2013). HFD was also efficacious against symp-
toms at metabolic, transcriptomic, and behavioral levels in these
mice (Scheibye‐Knudsen et al., 2014). Altogether, these studies sug-
gest that mouse models of progeria are especially susceptible to
food/caloric intake, and that ensuing proper energy intake can allow
in some cases a better recapitulation of the pathologies of the
human diseases.
Our study also shows that HFD alone cannot override the long‐
term detrimental effects of progerin expression in tissues, and that
the effect of other strategies with known benefits reducing progerin
toxicity in mice should be tested in combination with HFD. One of
the first strategies with reported benefits in progeria mice was the
treatment with farnesyltransferase inhibitors (FTIs). The success in
mice led to the use of lonafarnib in the first clinical trial in HGPS
patients. Lonafarnib treatment resulted in a modest improvement of
mean survival (1.6 years) and is currently the standard of care for
HGPS patients (Capell et al., 2008; Fong et al., 2006; Gordon et al.,
2012, 2014). Subsequent studies have identified different strategies
with benefit in progeria mice, including sodium salicylate (Osorio
et al., 2012), splicing therapies (Osorio et al., 2011), reprogramming
(Ocampo et al., 2016), and reduced NF‐κB signaling (Osorio et al.,
2012). Remarkably, the reported effects of all these strategies ame-
liorating disease and increasing lifespan are far more modest than
the effects of HFD. This suggests that these strategies might not be
able to ameliorate the combined features of cachexia and starvation
in the progeria mice as well as HFD. Thus, the benefit of these
strategies, and new strategies being developed to counteract pro-
gerin toxicity in vivo (rapamycin, antioxidants, remodelin, all‐trans
retinoic acid, 1,25α‐dihydroxy‐vitamin D3, pyrophosphate, etc; Cao
et al., 2011; Gabriel, Roedl, Gordon, & Djabali, 2015; Kreienkamp
et al., 2016, 2018; Larrieu, Britton, Demir, Rodriguez, & Jackson,
2014; Pellegrini et al., 2015; Villa‐Bellosta et al., 2013), should be
investigated in combination with HFD.
Overall, our findings suggest that metabolic features in HGPS
patients are an important area for investigation, as they might have
a more important contribution to disease pathology than previously
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thought. For instance, further studies are needed to identify molecu-
lar mechanisms responsible for the starvation/cachexia‐like pheno-
types in progeria mice. In addition, our study identified genes
involved in tissue homeostasis that are dysregulated in G609G mice.
Musculoskeletal problems remain a major challenge for HGPS
patients. Therefore, identifying transcriptome and proteome alter-
ations that might be targeted pharmacologically or nutraceutically
would be extremely useful for HGPS patients. In human disease,
stem cell depletion is considered a key contributor to HGPS pheno-
type (Rosengardten, McKenna, Grochova, & Eriksson, 2011). There is
growing evidence that energy balance and metabolic status are criti-
cal for stem cell function and life‐long tissue renewal (Suda, Takubo,
& Semenza, 2011). Future studies need to address whether meta-
bolic alterations drive stem cell exhaustion in progeria mice, and
whether HFD improves stem cell function, allowing slower aging of
these mice. Moreover, our lipidomics studies, which represent the
first completed in vivo lipidomic studies in progeria, reveal that lipid
alterations, if replicated in humans, might be a substantial contribu-
tor to atherosclerosis in HGPS patients. Particularly since LPCs are
elevated on HFD, which resembles features of the typical western‐
diet, greater attention should be paid to lipids and LPCs in HGPS
phenotype, especially given the known contribution of LPCs to
atherosclerosis (Schmitz & Ruebsaamen, 2010).
In summary, we propose that the combination of nutraceutical
and pharmacological strategies might provide the most benefit for
HGPS treatment, by targeting the multifactorial detrimental effects
of progerin expression in vivo.
4 | MATERIALS AND METHODS
4.1 | Mouse model of progeria
Mice carrying the human HGPS mutation (G609G) were generated in
the laboratory of Carlos Lopez‐Otin (C57BL/6 strain). Heterozygous
LmnaG609G/+ female and male mice were crossed to obtain WT mice
and mice carrying the mutation in homozygosis. LmnaG609G/G609G
(herein G609G mice) are the focus of this study. Littermates of the
same sex were randomly assigned to experimental groups.
G609G mice gain body mass at a slower rate than age‐matched
WT mice and are significantly smaller by four weeks of age. G609G
mice are infertile and show abnormal posture and marked curvature of
the spine, dying at ~100 days when fed a RC diet. Analyses of pheno-
types of mice were performed at different times throughout their lifes-
pan, and at time of death. Procedures performed in G609G mice
include: blood collection, food and water modifications, food depriva-
tion, NMR, performance tests, single housing, and tissue collection.
All animal studies were approved (protocol #2299) and conducted
in accordance with the Animal Studies Committee at Saint Louis
University (Dr. John C. Chrivia, Ph.D. is the Institutional Animal Care
and Use Committee Chair). The mice used in these studies were
housed at a constant temperature of 23°C with food and water pro-
vided ad libitum under a 12:12 light‐dark cycle, unless otherwise speci-
fied. Food intake and body weight were monitored daily in these
experiments and body composition was measured every week by
NMR (Bruker BioSpinLF50). Animals were fed either regular chow,
high‐fat diet, high‐cholesterol diet, or high‐protein diet. The composi-
tion of the different diets, as well as the catalog numbers of each diet
















Diet number 5,053 D17010902 TD.05305 D12492
kcal/g 3.0 3.9 4.5 5.2
%kcal protein 24.5 60.0 15.2 20.0
%kcal
carbohydrates
62.4 30.0 42.7 20.0
%kcal fat 13.1 10.0 42.0 60.0
4.2 | Comprehensive lab animal monitoring system
(CLAMS)
The Columbus Instruments (Columbus, OH) CLAMS system was uti-
lized to monitor the metabolic parameters of mice (male or female
G609G and WT littermates, at 7 weeks for chow or HFD). Five
G609G mice and six age‐matched WT mice were housed individually
in metabolic cages on a 12 hr day–night cycle, fed with either regular
chow (RC) or high fat diet (HFD). Mice were acclimated for 5 days in
the CLAMS unit. The hourly or average values during light and dark
period were calculated. Two‐way ANOVA follow by Bonferroni post‐
test was used to calculate the p value of statistical significance.
4.3 | Assessment of locomotor activity
Locomotor activity was assessed using mice housed in cages with
free access to running wheels. Briefly, after a 2 days’ acclimation
period to wheel‐equipped cages in a 12:12 light‐dark (LD), locomotor
activity was recorded over a 1‐week period. Wheel running data
were analyzed using Clocklab software (Actimetrics, Evanston, IL).
4.4 | Assessment of food intake and meal pattern
analysis
Meal structure was examined using an automated system for contin-
uous monitoring of food consumption (BiodaQ 2.3; Research Diets
Inc., New Brunswick, NJ) and BiodaQ 2.3 software. “Bouts” indicate
disturbance of the hopper and instability in scale readings suggesting
approach and investigation; actual changes in food mass were used
to estimate meal size. Meals were defined as bouts occurring within
5 min of each other and consumption of ≥0.02 g. After 2 days of
acclimation in BiodaQ cages, feeding behavior was established using
5 days of recordings.
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4.5 | Fecal analysis
For the analysis of fecal lipids, feces were collected from mice
housed individually in metabolic cages over a 24‐hr period. One‐hun-
dred‐milligram aliquots of feces were cleaned and dried for 1 hr at
70°C, incubated with 2 ml of chloroform‐methanol (2:1) for 30 min
at 60°C with constant agitation, and then centrifuged. Water (1 ml)
was added to the supernatant, and following vortexing, phase sepa-
ration was induced by low‐speed centrifugation (2,000 rpm for
10 min). The lower chloroform phase was then removed and trans-
ferred to a new tube, and the sample was evaporated to dryness.
Samples were then resuspended in 500 μl chloroform‐1% Triton X‐
100, evaporated to dryness, and finally resuspended in 500 μl of
water, so that the final solvent was 1% Triton X‐100 in water.
4.6 | Intestinal absorption of radioactive lipids
WT and G609G mice fed RC diet were fasted overnight, then gav-
aged with 100 µl olive oil containing 1 mCi/ml [14C]‐oleic acid. Blood
was collected from the inferior vena cava exactly 3 hr post gavage,
and radioactivity counted by liquid scintillation and normalized to
body weight.
4.7 | Glucose, Insulin, and Pyruvate tolerance tests
After 6‐hr fast, WT and G609G mice (n = 8) were injected intraperi-
toneally with glucose (2 g/kg of fat free mass), insulin (0.75 U/kg of
fat free mass), or pyruvate (2 g/kg of fat free mass; Sigma‐Aldrich, St
Louis MO, USA) to perform glucose tolerance test (GTT), insulin tol-
erance test (ITT) or pyruvate tolerance test (PTT) respectively. Blood
was collected by tail snip and glucose was measure before the injec-
tion (t = 0 min) and 15, 30, 60, and 120 min after injection using
OneTouch Ultra®2 glucometer.
4.8 | Histology
The proximal thoracic aorta was excissed, cleaned from surrounding
fat tissue, and divided into three fragments: ascending (from heart to
brachiocephalic braching), arch (from brachiocephalic to left subcla-
vian braching), and descending (after left subclavian braching). These
three segments were fixed 5 days in buffer containing 10% formalin,
5% sucrose, and 2 mmol/L EDTA, and subsequently embedded in
paraffin blocks. Four‐micrometer sections were then stained with
hematoxylin and eosin, following standard techniques.
4.9 | Immunoblotting
Mouse quadriceps were extracted at necropsy and flash frozen.
Quadriceps were then thawed and homogenized in 8 M urea. 80 mg
of total protein was loaded on 4%–15% Criterion TGX Gel. List of
antibodies used for immunoblotting in Supporting information
Reagents Table S1.
4.10 | Quantitative reverse‐transcription PCR
RNA was reverse transcribed to make cDNA using qScript™ cDNA
Synthesis Kit (Quanta biosciences) according to the manufacturer's
instructions. Real‐time PCR was performed using a SYBR‐green PCR
master mix kit (SYBR SELECT MASTER MIX; Life Technologies). List
of primers used in Supporting information Reagents Table S1.
4.11 | Statistical analysis
Quantification details of all the experiments performed, including the
gender and number of animals analyzed (N), are indicated in the fig-
ure legends. Statistical analyses were performed using Prism 7
(GraphPad Software, La Jolla, CA) or SPSS Statistics Version 23
(IBM). For simple comparisons between multiple groups, we per-
formed ANOVA; if p < 0.05 significance between groups was deter-
mined using post hoc analysis. For comparisons between groups,
Student's t test was used with Bonferroni correction. Data are pre-
sented as means ± SEM. Survival curves were generated using the
Kaplan–Meier method. Power was calculated using https://www.stat
stodo.com/SSizSurvival Pgm.php with the following data/assump-
tions: RC n = 12, HFD n = 11, HPD n = 7, HCD n = 7, alpha = 0.05.
RC vs HFD 2 tailed power = 0.94, RC vs HCD 2 tailed power =
0.94, HFD vs HCD 2 tailed power = 0.94, RC vs HPD tailed
power = 0.05. In all figures, * denotes p value of statistical signifi-
cance (*p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.0001).
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